Basilard BioTech Revenue and Competitors

We are Basilard BioTech. We are launching our novel gene delivery technology platform, SoloPoreâ„¢ to transform the rapidly growing cell-based therapies market. SoloPoreâ„¢ is a differentiated & superior solution for non-viral gene delivery. Cell and Gene Therapies (CGT) have immense potential to address unmet clinical needs by leveraging the power and diversity of cell functions. They offer the best hope for finding solutions to prevailing diseases that affect and kill millions of people. The main challenges now are improving upon the limitations of biological and ex-vivo gene delivery and scaling manufacturing (cost-effectively) to meet the needs of current/future cell therapies. This is the bottleneck SoloPoreâ„¢ addresses with our new, disruptive, IP-Protected mechanoporation solution that offers a better, mechanical (rather than biological), approach to gene delivery. In ex-vivo delivery, SoloPoreâ„¢ consistently achieves higher transfection and cell viability performance and yields vs. the industry leading bulk electroporation platform currently used widely. In viral delivery, SoloPoreâ„¢ provides greater scalability, safety, efficiency, & versatility than prevailing viral delivery methods, as well as lower cost & lead time. And SoloPoreâ„¢ is a superior platform for primary T cell engineering than both electroporation and the prevailing viral delivery methods.